Welcome to our dedicated page for Braveheart Bio news (Ticker: BRVE), a resource for investors and traders seeking the latest updates and insights on Braveheart Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Braveheart Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Braveheart Bio's position in the market.
Braveheart Bio (BRVE) will participate in the Stifel Virtual Cardiometabolic Forum on September 30, 2026. Management is scheduled for a fireside chat that day at 12:30 p.m. EDT.
Interested parties can access a live webcast of the session via the News & Events section of the Braveheart Bio investor relations website at https://ir.braveheart.bio/. A replay of the webcast will be available in a temporary archive on the site after the event.
Braveheart Bio (BRVE) reported second quarter 2026 results and initiated its Phase 3 LIONHEART-HCM trial of BHB-1893 in obstructive hypertrophic cardiomyopathy.
Cash and cash equivalents were $122.8 million as of June 30, 2026, rising to an as-adjusted $527.3 million when including approximately $404.5 million in net proceeds from the August 2026 IPO. Management estimates this funding will support operations into 2029. The IPO issued 24,437,500 shares at $18.00 per share for gross proceeds of about $439.9 million.
R&D expenses grew to $11.1 million and G&A to $4.8 million, driving a quarterly net loss of $15.0 million, or $2.51 per share attributable to common stockholders after a non-cash deemed dividend. Phase 3 LIONHEART-HCM in oHCM is enrolling, with first dosing expected in 2026 and interim results in the second half of 2027, while a global Phase 3 NOBLEHEART-HCM trial in nHCM is planned for the first half of 2027 following favorable Phase 2 data.
Braveheart Bio (Nasdaq: BRVE), a clinical-stage biopharmaceutical company focused on hypertrophic cardiomyopathy and other serious cardiovascular diseases, will participate in the Cantor Global Healthcare Conference in New York, held September 9-11, 2026.
Management is scheduled for a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT. A live webcast and replay will be accessible via the News & Events section of Braveheart Bio’s investor relations website.
Braveheart Bio (Nasdaq: BRVE) closed its upsized initial public offering, selling an aggregate 24,437,500 common shares at $18.00 per share, including 3,187,500 additional shares from the underwriters’ option.
The offering generated gross proceeds of approximately $439.9 million before expenses. All shares were sold by Braveheart Bio. The stock began trading on the Nasdaq Global Market on August 6, 2026 under ticker “BRVE”. Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor served as joint book-running managers. The registration statements became effective with the SEC on August 5, 2026.
Braveheart Bio (Nasdaq: BRVE) priced an upsized initial public offering of 21,250,000 common shares at $18.00 per share, all offered by the company. The shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026, with closing anticipated on August 7, 2026, subject to customary conditions.
Braveheart Bio granted underwriters a 30‑day option to buy up to an additional 3,187,500 shares at the IPO price, less underwriting discounts and commissions. According to the company, expected gross IPO proceeds are about $382.5 million, excluding any exercise of this option. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are joint book‑running managers.